Prelude Therapeutics Incorporated

SV Health Investors announced the final closing for its second Dementia Discovery Fund, DDF-2, with $269m in commitments from investors and non-profit organizations willing to put their money behind s

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Teams With Oblique On Antibody Di

Among the presentations at the European Society for Medical Oncology meeting in Barcelona, Spain will be data for older immune checkpoint inhibitors from Merck & Co., Inc. , AstraZeneca PLC and Br

SELLAS Life Sciences Group, Inc. is in a strong position in acute myeloid leukemia (AML) with positive data from a Phase IIa study of SLS009 and the completion of enrollment in its Phase III trial of